Free Trial

Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Norden Group LLC

Norden Group LLC raised its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 207.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,014 shares of the company's stock after buying an additional 3,385 shares during the quarter. Norden Group LLC's holdings in Medpace were worth $1,537,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Miller Howard Investments Inc. NY increased its holdings in shares of Medpace by 1.3% during the fourth quarter. Miller Howard Investments Inc. NY now owns 3,075 shares of the company's stock valued at $943,000 after acquiring an additional 39 shares in the last quarter. Schulhoff & Co. Inc. increased its holdings in shares of Medpace by 2.0% during the third quarter. Schulhoff & Co. Inc. now owns 2,250 shares of the company's stock valued at $545,000 after acquiring an additional 45 shares in the last quarter. Campbell Newman Asset Management Inc. increased its holdings in shares of Medpace by 0.4% during the fourth quarter. Campbell Newman Asset Management Inc. now owns 11,095 shares of the company's stock valued at $3,401,000 after acquiring an additional 46 shares in the last quarter. Treasurer of the State of North Carolina increased its holdings in shares of Medpace by 0.5% during the third quarter. Treasurer of the State of North Carolina now owns 10,230 shares of the company's stock valued at $2,477,000 after acquiring an additional 50 shares in the last quarter. Finally, Sectoral Asset Management Inc. increased its holdings in shares of Medpace by 4.9% during the third quarter. Sectoral Asset Management Inc. now owns 1,181 shares of the company's stock valued at $286,000 after acquiring an additional 55 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.


Medpace Stock Down 3.0 %

MEDP stock traded down $11.86 during midday trading on Tuesday, hitting $388.35. The company's stock had a trading volume of 233,565 shares, compared to its average volume of 250,501. The stock's 50-day moving average price is $398.09 and its 200 day moving average price is $328.45. Medpace Holdings, Inc. has a 1 year low of $197.39 and a 1 year high of $421.00. The stock has a market cap of $12.03 billion, a price-to-earnings ratio of 39.59, a PEG ratio of 1.97 and a beta of 1.38.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, beating analysts' consensus estimates of $2.45 by $0.75. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The firm had revenue of $511.00 million for the quarter, compared to analysts' expectations of $512.39 million. During the same quarter in the prior year, the firm earned $2.27 EPS. The business's revenue for the quarter was up 17.7% compared to the same quarter last year. As a group, equities analysts forecast that Medpace Holdings, Inc. will post 11.23 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Guggenheim boosted their price objective on Medpace from $453.00 to $464.00 and gave the company a "buy" rating in a report on Wednesday, April 24th. StockNews.com upgraded Medpace from a "hold" rating to a "buy" rating in a report on Tuesday, April 23rd. UBS Group upgraded Medpace from a "neutral" rating to a "buy" rating and upped their price target for the stock from $282.00 to $452.00 in a report on Thursday, February 15th. Robert W. Baird upped their price target on Medpace from $446.00 to $454.00 and gave the stock an "outperform" rating in a report on Wednesday, April 24th. Finally, Deutsche Bank Aktiengesellschaft began coverage on Medpace in a report on Monday, March 18th. They set a "hold" rating and a $395.00 price target for the company. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $443.00.

Get Our Latest Research Report on Medpace

Insider Activity

In other news, major shareholder Medpace Investors, Llc sold 50,000 shares of the company's stock in a transaction on Friday, February 16th. The stock was sold at an average price of $391.75, for a total transaction of $19,587,500.00. Following the transaction, the insider now owns 5,539,947 shares of the company's stock, valued at approximately $2,170,274,237.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, VP Susan E. Burwig sold 102 shares of the stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the sale, the vice president now owns 15,181 shares of the company's stock, valued at approximately $6,117,943. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Medpace Investors, Llc sold 50,000 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $391.75, for a total value of $19,587,500.00. Following the sale, the insider now directly owns 5,539,947 shares in the company, valued at approximately $2,170,274,237.25. The disclosure for this sale can be found here. Insiders have sold 189,340 shares of company stock valued at $76,651,647 in the last 90 days. Insiders own 20.30% of the company's stock.

Medpace Company Profile

(Free Report)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Featured Stories

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

→ Truth about Trump you’ve never heard (From Porter & Company) (Ad)

Should you invest $1,000 in Medpace right now?

Before you consider Medpace, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.

While Medpace currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Featured Articles and Offers

Search Headlines: